Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) CEO Adrian Adams purchased 500,000 shares of the company’s stock in a transaction dated Wednesday, March 15th. The shares were acquired at an average cost of $2.46 per share, for a total transaction of $1,230,000.00. Following the transaction, the chief executive officer now owns 3,569,230 shares of the company’s stock, valued at $8,780,305.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) traded up 7.11% during midday trading on Monday, hitting $2.41. The stock had a trading volume of 3,463,571 shares. The company’s 50 day moving average price is $3.88 and its 200-day moving average price is $4.58. The stock’s market capitalization is $157.86 million. Aralez Pharmaceuticals Inc has a 52 week low of $2.05 and a 52 week high of $6.80.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Monday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.11. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. The firm earned $20 million during the quarter, compared to analyst estimates of $21.86 million. During the same period in the previous year, the company earned ($0.40) EPS. Aralez Pharmaceuticals’s revenue for the quarter was up 233.3% on a year-over-year basis. Equities analysts anticipate that Aralez Pharmaceuticals Inc will post ($1.07) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Your IP Address:

Institutional investors have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Aralez Pharmaceuticals during the fourth quarter worth about $103,000. Shufro Rose & Co. LLC boosted its position in shares of Aralez Pharmaceuticals by 30.3% in the third quarter. Shufro Rose & Co. LLC now owns 21,487 shares of the company’s stock worth $104,000 after buying an additional 5,000 shares during the last quarter. J. Goldman & Co LP purchased a new position in shares of Aralez Pharmaceuticals during the fourth quarter worth about $198,000. Nwam LLC purchased a new position in shares of Aralez Pharmaceuticals during the third quarter worth about $228,000. Finally, FNY Managed Accounts LLC boosted its position in shares of Aralez Pharmaceuticals by 13.5% in the third quarter. FNY Managed Accounts LLC now owns 59,000 shares of the company’s stock worth $286,000 after buying an additional 7,000 shares during the last quarter. 44.01% of the stock is owned by institutional investors and hedge funds.

Separately, Chardan Capital dropped their price target on Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, March 15th.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.